Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-Muscle Invasive Bladder Neoplasms 1Myelodysplastic Syndromes 1Metabolism, Inborn Errors 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Immunologic Deficiency Syndromes 1Hemoglobinopathies 1Graft vs Host Disease 1Congenital Bone Marrow Failure Syndromes 1Carcinoma in Situ 1Bone Marrow Failure Disorders 1Anemia, Refractory, with Excess of Blasts 1

Interventions

asciminib 15Cyclophosphamide 12fludarabine phosphate 10Mycophenolic Acid 9fludarabine 8nilotinib 7Whole-Body Irradiation 7Imatinib Mesylate 6Dasatinib 6Tacrolimus 5Sirolimus 5Cyclosporine 5venetoclax 4bosutinib 4Melphalan 4Granulocyte Colony-Stimulating Factor 4ponatinib 3Thiotepa 3Stem Cell Transplantation 3Peripheral Blood Stem Cell Transplantation 3Cyclosporins 3Busulfan 3thymoglobulin 2ruxolitinib 2Specimen Handling 2Mesna 2Magnetic Resonance Spectroscopy 2Filgrastim 2Blood Component Removal 2treosulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clinical Trials, Phase I as Topic × 90 days × Clear all
NCT03533816 2026-03-25

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

University of Kansas Medical Center

Phase 1 Recruiting
38 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡